Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.740
+0.150 (3.27%)
Apr 13, 2026, 1:08 PM EDT - Market open
Foghorn Therapeutics Revenue
In the year 2025, Foghorn Therapeutics had annual revenue of $30.91M with 36.75% growth. Foghorn Therapeutics had revenue of $9.25M in the quarter ending December 31, 2025, with 223.77% growth.
Revenue (ttm)
$30.91M
Revenue Growth
+36.75%
P/S Ratio
8.98
Revenue / Employee
$291,594
Employees
106
Market Cap
278.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.91M | 8.31M | 36.75% |
| Dec 31, 2024 | 22.60M | -11.55M | -33.83% |
| Dec 31, 2023 | 34.16M | 14.93M | 77.63% |
| Dec 31, 2022 | 19.23M | 17.91M | 1,357.77% |
| Dec 31, 2021 | 1.32M | 889.00K | 206.74% |
| Dec 31, 2020 | 430.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 79.59M |
| Alector | 21.05M |
| LENZ Therapeutics | 19.09M |
| Abeona Therapeutics | 5.82M |
| Silence Therapeutics | 559.00K |
| SAB Biotherapeutics | 114.70K |
FHTX News
- 4 days ago - Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - GlobeNewsWire
- 4 weeks ago - Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - GlobeNewsWire
- 6 weeks ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 3 months ago - Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - GlobeNewsWire
- 3 months ago - Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire